Table 6 Total fatty acids of HBV cirrhosis patients in comparison of controls

C-14:0

1.00 ± 0.9

0.88 ± 0.7

C-16 : 0

18.01 ± 4.0

24.54 ± 3.4^*

C-18 : 0

16.00 ± 4.6

15.77 ± 3.4

C-20 : 0

0.78 ± 0.6

0.21 ± 0.3^*

C-24 : 0

0.02 ± 0.06

0.07 ± 0.2

C-14 : 1

0.17 ± 0.4

0.26 ± 0.4

C-16 : 1

2.03 ± 1.6

4.65 ± 0.7^*

C-18 : 1

22.18 ± 4.8

23.70 ± 2.9

C-22 : 1

1.75 ± 1.4

1.38 ± 0.9

C-24 : 1

0.18 ± 0.5

ND

C-18 : 2

28.72 ± 3.3

22.75 ± 3.2^*

C-18 : 3

0.59 ± 0.9

0.12 ± 0.3

C-20 : 3

1.35 ± 0.9

0.09 ± 0.1^*

C-20 : 4

6.31 ± 1.0

3.57 ± 0.8^*

C-20 : 5

0.71 ± 0.3

ND^*

C-22 : 5

0.33 ± 0.6

0.87 ± 0.8

C-22 : 6

0.50 ± 0.6

0.51 ± 0.7

C-16 : 1: C-16 : 0

0.1

0.2

C-18 : 1: C-18 : 0

1.3

1.5

PUFA : SFA

1.5

0.6